Jane Street Group, LLC Acadia Pharmaceuticals Inc Transaction History

Jane Street Group, LLC

  • $445 Billion
  • Q3 2024

A detailed history of Jane Street Group, LLC transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Jane Street Group, LLC holds 135,452 shares of ACAD stock, worth $2.29 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
135,452
Previous 498,225 72.81%
Holding current value
$2.29 Million
Previous $8.1 Million 74.26%
% of portfolio
0.0%
Previous 0.01%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$15.14 - $19.14 $5.49 Million - $6.94 Million
-362,773 Reduced 72.81%
135,452 $2.08 Million
Q2 2024

Aug 14, 2024
BUY
$14.62 - $18.42 $1.79 Million - $2.25 Million
122,164 Added 32.49%
498,225 $8.1 Million
Q1 2024

May 15, 2024
SELL
$17.79 - $30.86 $1.25 Million - $2.17 Million
-70,256 Reduced 15.74%
376,061 $6.95 Million
Q4 2023

Feb 14, 2024
BUY
$20.78 - $31.77 $2.67 Million - $4.08 Million
128,354 Added 40.37%
446,317 $14 Million
Q3 2023

Nov 14, 2023
BUY
$20.84 - $33.47 $4.27 Million - $6.86 Million
204,880 Added 181.18%
317,963 $6.63 Million
Q2 2023

Aug 14, 2023
SELL
$17.8 - $25.65 $94,233 - $135,791
-5,294 Reduced 4.47%
113,083 $2.71 Million
Q1 2023

May 15, 2023
BUY
$16.32 - $20.92 $1.7 Million - $2.19 Million
104,453 Added 750.17%
118,377 $2.23 Million
Q4 2022

Feb 14, 2023
SELL
$14.2 - $18.63 $750,044 - $984,036
-52,820 Reduced 79.14%
13,924 $221,000
Q3 2022

Nov 14, 2022
BUY
$14.11 - $18.27 $74,021 - $95,844
5,246 Added 8.53%
66,744 $1.09 Million
Q2 2022

Aug 16, 2022
SELL
$13.01 - $27.22 $356,187 - $745,229
-27,378 Reduced 30.8%
61,498 $866,000
Q1 2022

May 17, 2022
SELL
$20.94 - $27.5 $1.1 Million - $1.44 Million
-52,486 Reduced 37.13%
88,876 $2.15 Million
Q4 2021

Feb 15, 2022
BUY
$16.79 - $27.09 $1.37 Million - $2.21 Million
81,480 Added 136.07%
141,362 $3.3 Million
Q3 2021

Nov 16, 2021
SELL
$15.78 - $24.77 $362,324 - $568,743
-22,961 Reduced 27.72%
59,882 $994,000
Q2 2021

Aug 16, 2021
SELL
$19.4 - $27.42 $1.24 Million - $1.75 Million
-63,939 Reduced 43.56%
82,843 $2.02 Million
Q1 2021

May 18, 2021
BUY
$25.02 - $54.99 $1.84 Million - $4.04 Million
73,390 Added 100.0%
146,782 $3.79 Million
Q4 2020

Feb 17, 2021
SELL
$41.04 - $56.79 $280,426 - $388,046
-6,833 Reduced 8.52%
73,392 $3.92 Million
Q3 2020

Nov 17, 2020
SELL
$36.42 - $57.0 $6.48 Million - $10.1 Million
-177,983 Reduced 68.93%
80,225 $3.31 Million
Q2 2020

Aug 17, 2020
BUY
$39.26 - $52.73 $8.91 Million - $12 Million
226,999 Added 727.35%
258,208 $12.5 Million
Q4 2019

Feb 14, 2020
SELL
$36.21 - $51.4 $400,555 - $568,586
-11,062 Reduced 26.17%
31,209 $1.34 Million
Q3 2019

Nov 14, 2019
BUY
$22.22 - $44.01 $197,646 - $391,468
8,895 Added 26.65%
42,271 $1.52 Million
Q2 2019

Aug 15, 2019
SELL
$23.32 - $28.12 $634,817 - $765,482
-27,222 Reduced 44.92%
33,376 $892,000
Q1 2019

May 16, 2019
SELL
$16.17 - $27.38 $429,830 - $727,815
-26,582 Reduced 30.49%
60,598 $1.63 Million
Q4 2018

Feb 15, 2019
SELL
$14.32 - $22.92 $336,305 - $538,276
-23,485 Reduced 21.22%
87,180 $1.41 Million
Q3 2018

Nov 14, 2018
BUY
$13.03 - $21.81 $1.23 Million - $2.05 Million
94,062 Added 566.54%
110,665 $2.3 Million
Q2 2018

Aug 15, 2018
BUY
$15.07 - $22.34 $48,374 - $71,711
3,210 Added 23.97%
16,603 $254,000
Q1 2018

May 15, 2018
BUY
$22.47 - $32.33 $144,122 - $207,364
6,414 Added 91.9%
13,393 $301,000
Q3 2017

Nov 14, 2017
BUY
$29.49 - $38.37 $205,810 - $267,784
6,979
6,979 $263,000

Others Institutions Holding ACAD

# of Institutions
279
Shares Held
156M
Call Options Held
901K
Put Options Held
314K
View Full List

About ACADIA PHARMACEUTICALS INC

ACAD Quotes by TradingView
  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.73B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email